Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: update after 48 weeks.
Questions
1. What are the unmet needs in the treatment of resistant/intolerant chronic phase chronic myeloid leukaemia (CML)? (00:12-01:04)
2. What is asciminib and what is the rationale for its use in the treatment of CML? (01:04-02:16)
3. Could you give us a brief overview of the ASCEMBL trial? (02:16-03:02)
4. What were the findings in terms of major molecular response at week 48 and how did they compare with week 24? (03:02-04:30)
5. In what indications has asciminib recently been approved by the FDA? (04:30-05:45)
Speaker Disclosure: Michael Mauro discloses clinical trial support (institutional) from Novartis, Bristol Myers Squibb, Takeda and Sun Pharma/SPARC. He also discloses consultancy for Novartis, Bristol Myers Squibb, Takeda, Pfizer and Sun Pharma/SPARC.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
